ALK and non-small cell lung carcinoma: For patients with NSCLC harboring an ALK (anaplastic lymphoma kinase) rearrangement mutation, characterized by inversion of the EML4 and ALK genes on chromosome 2 that typically occurs in young, non-smoking individuals, molecular targeted therapy using ALK TKIs can also be used to inhibit expression of this newly formed oncogene [20].